Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
Helena A YuLuis G Paz-AresJames Chih-Hsin YangKi Hyeong LeePilar Garrido LopezKeunchil ParkJoo-Hang KimHuzhang MaoSameera R WijayawardanaLing GaoRebecca R HozakBo H ChaoDavid PlanchardPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Ramucirumab plus osimertinib demonstrated encouraging safety and antitumor activity in T790M-positive EGFR-mutant NSCLC.See related commentary by Garon, p. 905.